III期-话题@MedSci

#III期#

681篇内容 | 2793人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1594607, encodeId=cf01159460e22, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=阿斯利康的酪氨酸激酶抑制剂Calquence在III期白血病试验中达到终点, objectType=article, longId=167833, objectId=1f1d16e833ae, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1f1d16e833ae, replyNumber=0, likeNumber=53, createdTime=2019-06-09, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1f1d16e833ae, moduleTitle=阿斯利康的酪氨酸激酶抑制剂Calquence在III期白血病试验中达到终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1f1d16e833ae)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594606, encodeId=65f5159460684, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=Lancet Oncol：伊匹单抗联合纳武单抗治疗III期黑色素瘤的更佳剂量方案, objectType=article, longId=167664, objectId=fffd16e664b7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fffd16e664b7, replyNumber=0, likeNumber=63, createdTime=2019-06-06, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fffd16e664b7, moduleTitle=Lancet Oncol：伊匹单抗联合纳武单抗治疗III期黑色素瘤的更佳剂量方案, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fffd16e664b7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594605, encodeId=e133159460520, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=Lancet oncol：新辅助药物达拉非尼联合曲美替尼疗法用于III期黑色素瘤的疗效评估, objectType=article, longId=167652, objectId=245216e65298, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=245216e65298, replyNumber=0, likeNumber=20, createdTime=2019-06-06, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=245216e65298, moduleTitle=Lancet oncol：新辅助药物达拉非尼联合曲美替尼疗法用于III期黑色素瘤的疗效评估, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=245216e65298)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594604, encodeId=a0ef15946048d, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=2019 ASCO：Janssen抗CD38单抗Darzalex治疗多发性骨髓瘤III期数据喜人, objectType=article, longId=167615, objectId=3d4d16e61584, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3d4d16e61584, replyNumber=0, likeNumber=54, createdTime=2019-06-05, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3d4d16e61584, moduleTitle=2019 ASCO：Janssen抗CD38单抗Darzalex治疗多发性骨髓瘤III期数据喜人, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3d4d16e61584)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594603, encodeId=61481594603c6, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=2019ASCO：诺华的CDK4/6抑制剂Kisqali在III期晚期乳腺癌试验中提前到达终点, objectType=article, longId=167612, objectId=933416e61276, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=933416e61276, replyNumber=0, likeNumber=85, createdTime=2019-06-05, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=933416e61276, moduleTitle=2019ASCO：诺华的CDK4/6抑制剂Kisqali在III期晚期乳腺癌试验中提前到达终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=933416e61276)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594602, encodeId=3e001594602f0, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=2019ASCO：阿斯利康的PARP抑制剂Lynparza，在胰腺癌III期临床中表现出色, objectType=article, longId=167610, objectId=0be116e61073, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0be116e61073, replyNumber=0, likeNumber=78, createdTime=2019-06-05, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0be116e61073, moduleTitle=2019ASCO：阿斯利康的PARP抑制剂Lynparza，在胰腺癌III期临床中表现出色, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0be116e61073)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594601, encodeId=55ad159460128, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=诺华IgE单抗Xolair治疗慢性鼻窦炎的两项III期研究达到主要临床终点, objectType=article, longId=167609, objectId=9e4316e6096f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9e4316e6096f, replyNumber=0, likeNumber=58, createdTime=2019-06-05, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9e4316e6096f, moduleTitle=诺华IgE单抗Xolair治疗慢性鼻窦炎的两项III期研究达到主要临床终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9e4316e6096f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594600, encodeId=ccc515946005b, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=BioMarin的血友病基因疗法III期临床达到终点，但其长期效应引起质疑, objectType=article, longId=167518, objectId=665116e51869, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=665116e51869, replyNumber=0, likeNumber=44, createdTime=2019-06-04, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=665116e51869, moduleTitle=BioMarin的血友病基因疗法III期临床达到终点，但其长期效应引起质疑, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=665116e51869)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594599, encodeId=847615945992c, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=The Lancet：Abbvie口服JAK1抑制剂upadacitinib治疗类风湿性关节炎III期阳性试验结果, objectType=article, longId=167491, objectId=1e2a16e491c8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1e2a16e491c8, replyNumber=0, likeNumber=21, createdTime=2019-06-03, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1e2a16e491c8, moduleTitle=The Lancet：Abbvie口服JAK1抑制剂upadacitinib治疗类风湿性关节炎III期阳性试验结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1e2a16e491c8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594598, encodeId=e874159459815, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=诺华的吸入型联合疗法QMF149治疗哮喘III期试验达到实验终点, objectType=article, longId=167489, objectId=a85316e489c3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a85316e489c3, replyNumber=0, likeNumber=84, createdTime=2019-06-03, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a85316e489c3, moduleTitle=诺华的吸入型联合疗法QMF149治疗哮喘III期试验达到实验终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a85316e489c3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594597, encodeId=6604159459e2b, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=辉瑞公布LYRICA（普瑞巴林）治疗原发性全身强直-阵挛性癫痫发作的III期临床试验结果, objectType=article, longId=166801, objectId=1b1b16680115, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1b1b16680115, replyNumber=0, likeNumber=93, createdTime=2019-05-27, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1b1b16680115, moduleTitle=辉瑞公布LYRICA（普瑞巴林）治疗原发性全身强直-阵挛性癫痫发作的III期临床试验结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1b1b16680115)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594596, encodeId=47ce1594596c2, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=晚期卵巢癌：Rubraca的III期ARIEL3研究的全新数据, objectType=article, longId=166644, objectId=25351666441e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=25351666441e, replyNumber=0, likeNumber=53, createdTime=2019-05-24, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=25351666441e, moduleTitle=晚期卵巢癌：Rubraca的III期ARIEL3研究的全新数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=25351666441e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594595, encodeId=55eb15945953a, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=DCR：肌肉和脂肪组织对I期至III期结直肠癌患者长期生存的影响, objectType=article, longId=166623, objectId=ae3c166623b3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ae3c166623b3, replyNumber=0, likeNumber=51, createdTime=2019-05-24, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ae3c166623b3, moduleTitle=DCR：肌肉和脂肪组织对I期至III期结直肠癌患者长期生存的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ae3c166623b3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594594, encodeId=aad51594594ec, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=早产儿坏死性小肠结肠炎：IBT和FDA就III期研究的设计达成一致, objectType=article, longId=166544, objectId=2a63166544a6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2a63166544a6, replyNumber=0, likeNumber=70, createdTime=2019-05-23, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2a63166544a6, moduleTitle=早产儿坏死性小肠结肠炎：IBT和FDA就III期研究的设计达成一致, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2a63166544a6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594593, encodeId=304815945938c, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=罗沙司他全球III期临床研究证实其心血管安全性, objectType=article, longId=166305, objectId=121416630562, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=121416630562, replyNumber=0, likeNumber=75, createdTime=2019-05-19, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=121416630562, moduleTitle=罗沙司他全球III期临床研究证实其心血管安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=121416630562)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594592, encodeId=d1581594592f0, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=辉瑞公布其JAK1口服抑制剂治疗特应性皮炎III期临床的阳性结果, objectType=article, longId=166254, objectId=0b72166254e3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0b72166254e3, replyNumber=0, likeNumber=61, createdTime=2019-05-18, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0b72166254e3, moduleTitle=辉瑞公布其JAK1口服抑制剂治疗特应性皮炎III期临床的阳性结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0b72166254e3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594591, encodeId=f810159459144, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=全球III期临床研究：roxadustat的心血管安全性得到证实, objectType=article, longId=165928, objectId=8d7416592893, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8d7416592893, replyNumber=0, likeNumber=71, createdTime=2019-05-14, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8d7416592893, moduleTitle=全球III期临床研究：roxadustat的心血管安全性得到证实, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8d7416592893)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594590, encodeId=c43e159459058, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=III期临床试验证实Fc融合凝血因子延长半衰期，可为血友病患者提供有效的围手术期止血, objectType=article, longId=165917, objectId=84ae16591e2f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=84ae16591e2f, replyNumber=0, likeNumber=95, createdTime=2019-05-14, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=84ae16591e2f, moduleTitle=III期临床试验证实Fc融合凝血因子延长半衰期，可为血友病患者提供有效的围手术期止血, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=84ae16591e2f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594589, encodeId=c9b11594589b0, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=慢性淋巴细胞白血病：Calquence达到III期临床试验的主要终点, objectType=article, longId=165652, objectId=69a116565258, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=69a116565258, replyNumber=0, likeNumber=54, createdTime=2019-05-09, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=69a116565258, moduleTitle=慢性淋巴细胞白血病：Calquence达到III期临床试验的主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=69a116565258)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594588, encodeId=b72e159458824, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=NEJM：SOLIRIS（eculizumab）治疗神经脊髓炎视觉障碍的III期阳性数据, objectType=article, longId=165432, objectId=e87616543228, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e87616543228, replyNumber=0, likeNumber=56, createdTime=2019-05-07, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e87616543228, moduleTitle=NEJM：SOLIRIS（eculizumab）治疗神经脊髓炎视觉障碍的III期阳性数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e87616543228)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

III期

2020-05-29

智智灵药 (审核中...)

前往app查看评论内容

#III期#

阿斯利康的酪氨酸激酶抑制剂Calquence在III期白血病试验中达到终点

2019-06-09

智智灵药 (审核中...)

前往app查看评论内容

#III期#

Lancet Oncol：伊匹单抗联合纳武单抗治疗III期黑色素瘤的更佳剂量方案

2019-06-06

智智灵药 (审核中...)

前往app查看评论内容

#III期#

Lancet oncol：新辅助药物达拉非尼联合曲美替尼疗法用于III期黑色素瘤的疗效评估

2019-06-06

智智灵药 (审核中...)

前往app查看评论内容

#III期#

2019 ASCO：Janssen抗CD38单抗Darzalex治疗多发性骨髓瘤III期数据喜人

2019-06-05

智智灵药 (审核中...)

前往app查看评论内容

#III期#

2019ASCO：诺华的CDK4/6抑制剂Kisqali在III期晚期乳腺癌试验中提前到达终点

2019-06-05

智智灵药 (审核中...)

前往app查看评论内容

#III期#

2019ASCO：阿斯利康的PARP抑制剂Lynparza，在胰腺癌III期临床中表现出色

2019-06-05

智智灵药 (审核中...)

前往app查看评论内容

#III期#

诺华IgE单抗Xolair治疗慢性鼻窦炎的两项III期研究达到主要临床终点

2019-06-05

智智灵药 (审核中...)

前往app查看评论内容

#III期#

BioMarin的血友病基因疗法III期临床达到终点，但其长期效应引起质疑

2019-06-04

智智灵药 (审核中...)

前往app查看评论内容

#III期#

The Lancet：Abbvie口服JAK1抑制剂upadacitinib治疗类风湿性关节炎III期阳性试验结果

2019-06-03

智智灵药 (审核中...)

前往app查看评论内容

#III期#

诺华的吸入型联合疗法QMF149治疗哮喘III期试验达到实验终点

2019-06-03

智智灵药 (审核中...)

前往app查看评论内容

#III期#

辉瑞公布LYRICA（普瑞巴林）治疗原发性全身强直-阵挛性癫痫发作的III期临床试验结果

2019-05-27

智智灵药 (审核中...)

前往app查看评论内容

#III期#

晚期卵巢癌：Rubraca的III期ARIEL3研究的全新数据

2019-05-24

智智灵药 (审核中...)

前往app查看评论内容

#III期#

DCR：肌肉和脂肪组织对I期至III期结直肠癌患者长期生存的影响

2019-05-24

智智灵药 (审核中...)

前往app查看评论内容

#III期#

早产儿坏死性小肠结肠炎：IBT和FDA就III期研究的设计达成一致

2019-05-23

智智灵药 (审核中...)

前往app查看评论内容

#III期#

罗沙司他全球III期临床研究证实其心血管安全性

2019-05-19

智智灵药 (审核中...)

前往app查看评论内容

#III期#

辉瑞公布其JAK1口服抑制剂治疗特应性皮炎III期临床的阳性结果

2019-05-18

智智灵药 (审核中...)

前往app查看评论内容

#III期#

全球III期临床研究：roxadustat的心血管安全性得到证实

2019-05-14

智智灵药 (审核中...)

前往app查看评论内容

#III期#

III期临床试验证实Fc融合凝血因子延长半衰期，可为血友病患者提供有效的围手术期止血

2019-05-14

智智灵药 (审核中...)

前往app查看评论内容

#III期#

慢性淋巴细胞白血病：Calquence达到III期临床试验的主要终点

2019-05-09

智智灵药 (审核中...)

前往app查看评论内容

#III期#

NEJM：SOLIRIS（eculizumab）治疗神经脊髓炎视觉障碍的III期阳性数据

2019-05-07

科室
- - 订阅+
  - 更多科室
工具
服务